Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Discovery of massive spider's web in Greece reveals unexpected behavior - 2Yemen’s Aden airport shut by STC-backed transport minister, Saudi source says
- 3From record warming to rusting rivers, 2025 Arctic Report Card shows a region transforming faster than expected
- 4Find the Advantages of Deep rooted Getting the hang of: Extending Information and Self-awareness
- 5Glamour Shots once ruled the mall. I went to one of the last ones standing.
- Instructions to Pick the Right Gold Speculation Procedure: Exploring the Market
- Sheinelle Jones will cohost fourth hour of 'Today' with Jenna Bush Hager: Here's what to know about her
- US FDA declines to approve Corcept's drug for rare hormonal disorder
- Why doing good also makes us feel good, during the holidays and beyond
- Mating injuries may lead scientists to identify dinosaurs’ sex
- Fundamental Monetary Guidance for Going into Business
- The Ascent of Rousing Pioneers Who Formed History
- 5 High Limit Outer Hard Drives For Information Stockpiling
- Vote In favor of Your Favored Shades
